Erik Ingelsson
Fortuna: 578 145 $ al 31/05/2026
Fortuna: 578 145 $ al 31/05/2026
Erik Ingelsson currently works at Wave Life Sciences Ltd., as Chief Scientific Officer from 2024.
Dr. Ingelsson also formerly worked at GSK Plc, as Senior Vice President & Head-Target Discovery and Stanford University, as Professor-Medicine from 2015 to 2019.
Dr. Ingelsson received his doctorate degree from the University of Uppsala.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
WAVE LIFE SCIENCES LTD. 0,05 % | 09/04/2026 | 87.864 ( 0,05 % ) | 578 145 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| WAVE LIFE SCIENCES LTD. | Director Técnico/Científico/I+D | 09/05/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2019 |
| GSK PLC | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Wave Life Sciences Ltd.
Wave Life Sciences Ltd. BiotechnologyHealth Technology Operates as a biotechnology company that develops RNA oligonucleotides medicines | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Uppsala
University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.